The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 708K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

11 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of Tricyclic Clerodane Diterpenes as Sarco/Endoplasmic Reticulum Ca(2+)-ATPase Inhibitors and Structure-Activity Relationships.EBI
Albert-Ludwigs-University of Freiburg
Water-mediated interactions influence the binding of thapsigargin to sarco/endoplasmic reticulum calcium adenosinetriphosphatase.EBI
University of Copenhagen
Elucidation of the topography of the thapsigargin binding site in the sarco-endoplasmic calcium ATPase.EBI
University of Copenhagen
Amphiphilic glycoconjugates as potential anti-cancer chemotherapeutics.EBI
Emory University
Applying linear interaction energy method for rational design of noncompetitive allosteric inhibitors of the sarco- and endoplasmic reticulum calcium-ATPase.EBI
Johns Hopkins University
Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.EBI
The Ohio State University
Phenolic Compounds from EBI
Centre of Experimental Medicine
Sarco/Endoplasmic Reticulum Calcium ATPase Inhibitors: Beyond Anticancer Perspective.EBI
University of Chemistry and Technology Prague
Carbazole compounds useful as bromodomain inhibitorsBDB
Bristol-Myers Squibb
Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.BDB
Bristol-Myers Squibb Pharmaceutical Research Institute